Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine and High-Dose Palbociclib in HR+/HER2- Advanced Breast Cancer
NCT07061717Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jul 2025
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hydroxychloroquine in Hormone-Receptor-Positive Breast Cancer (3 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Progression-Free Survival at 3 years. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT07061717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07061717.